Previous 10 |
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “ Company ”) today announced that, further to its Open Market Sale Agreement with Jefferies LLC previously disclosed on November 30, 2018, in relation to at-the-market (“ATM”) offerings of common shares in ...
The USPTO has issued a notice of allowance to Aurinia Pharmaceuticals (NASDAQ: AUPH ) for patent application 15/835,219, entitled “PROTOCOL FOR TREATMENT OF LUPUS NEPHRITIS”. More news on: Aurinia Pharmaceuticals Inc., Healthcare stocks news, Stocks on the move, ...
Allowed claims cover an individualized flat-dosed pharmacodynamic treatment protocol utilized in the AURA-LV study and the ongoing AURORA study in lupus nephritis Claims have the potential to protect voclosporin’s method of use and dosing protocol for LN until December 2037 ...
Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced its Chairman and Chief Executive Officer, Richard M. Glickman, will present a corporate overview at the 8 th Annual SVB Leerink Global Healthcare Conference in NYC on February 27, 2019 at 2:30pm ET. The presentation wi...
NEW YORK, Jan. 30, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Leidos Holdings, Inc. (NYSE:LDOS), Nomad Foods Limited (NYSE:NOMD), Hu...
News, Short Squeeze, Breakout and More Instantly...
Aurinia Pharmaceuticals Inc Company Name:
AUPH Stock Symbol:
NASDAQ Market:
Aurinia Pharmaceuticals Inc Website:
Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...
Company achieved $57.2 million in total net revenue and $55.0 million in net product revenue for the second quarter of 2024, representing year-over-year growth of approximately 38% and 34% respectively Company generated approximately $15.8 million in free cash flow in the second quarter a...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2024 on Thursday, August 1, 2024, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30...